I promised a reference for which talk at ASCO discussed the diminishing returns for
 

2nd,3rd, 4th,and so on line chemotherapy for recurrent metastatic breast cancer and how that differed for her2 targeted therapies for her2+ patients.

It was from


Therapeutic Options for Treatment Refractory Breast Cancer: Discussion
Harold J. Burstein, MD, PhD
Discussant

Given on the last day of ASCO

It is a video included in the virtual meeting which will be available free @ the beginning of December.